ReviewCold Spring Harbor perspectives in medicine2016
Antibacterial Antifolates: From Development through Resistance to the Next Generation.
Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 77 citations in OpenAlex.
- Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions.BMC pharmacology & toxicology · 2024Trial
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- A thiadiazolylidene-morpholine compound inhibits Pseudomonas aeruginosa by destabilizing the thiamine monophosphate kinase thiL.The Journal of biological chemistry · 2026Article
- The effect of biochanin A on the antibiotic susceptibilities of Escherichia coli grown under different respiration and metabolic conditions on agar media.BMC microbiology · 2026Article
- Preparation of Lipophilic Derivatives ofACS omega · 2025Article
- Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions.Journal of evaluation in clinical practice · 2025Review
- Comprehensive genome analysis ofVeterinary world · 2025Article
- Perturbation ofmBio · 2025Article
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
- Discovery of novel targets for important human and plant fungal pathogens via an automated computational pipeline HitList.PloS one · 2025Article
- Discovery of New Natural Phytocompounds: The Modern Tools to Fight Against Traditional Bacterial Pathogens.Current pharmaceutical biotechnology · 2025Review
- PanARGMiner (Pan-Genomic Antimicrobial Resistance Gene Miner): An advanced feature selection framework for extracting key resistance genes from pan-genomic datasets.Computational and structural biotechnology journal · 2025Article
- Exploring the metabolic profile of A. baumannii for antimicrobial development using genome-scale modeling.PLoS pathogens · 2024Article
- Wiring Between Close Nodes in Molecular Networks Evolves More Quickly Than Between Distant Nodes.Molecular biology and evolution · 2024Article
- Computational Studies on 6-Pyruvoyl Tetrahydropterin Synthase (6-PTPS) ofBioinformatics and biology insights · 2024Article
- The Vibrio cholerae CBASS phage defence system modulates resistance and killing by antifolate antibiotics.Nature microbiology · 2024Article
- Identification of a Potential Antimycobacterial Drug Sensitizer Targeting a Flavin-Independent Methylenetetrahydrofolate Reductase.ACS omega · 2023Article
- Current Understanding of Potential Linkages between Biocide Tolerance and Antibiotic Cross-Resistance.Microorganisms · 2023Review
- Folate-mediated one-carbon metabolism as a potential antifungal target for the sustainable cultivation of microalga Haematococcus pluvialis.Biotechnology for biofuels and bioproducts · 2023Article
- Structural insights into translation regulation by the THF-II riboswitch.Nucleic acids research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The folate cycle is one of the key metabolic pathways used by bacteria to synthesize vital building blocks required for proliferation. Therapeutic agents targeting enzymes in this cycle, such as trimethoprim and sulfamethoxazole, are among some of the most important and continually used antibacterials to treat both Gram-positive and Gram-negative pathogens. As with all antibacterial agents, the emergence of resistance threatens the continued clinical use of these life-saving drugs. In this article, we describe and analyze resistance mechanisms that have been clinically observed and review newer generations of preclinical compounds designed to overcome the molecular basis of the resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.